Some studies believe that factors such as previous surgical history, asthma status, peripheral blood eosinophil count, IgE, and IL-5 levels do not significantly influence the efficacy of monoclonal antibodies.4, 25 Conversely, other research found that patients with increased baseline peripheral blood eosinophil levels exhibit better responses to benralizumab and mepolizumab treatment, and that baseline serum osteoprotegerin levels can serve as a biological marker for predicting the response to dupilumab.26 This evidence concerns the gene IGHE and asthma.